Skip to main content

Table 1 Participants demographics and clinical characteristics (Mean ± Standard Error)

From: Remote at-home wearable-based gait assessments in Progressive Supranuclear Palsy compared to Parkinson’s Disease

 

PD

(n = 10)

PSP

(n = 10)

p-value

Cohen’s d

Demographics

 Age, years

70.3 ± 1.8

67.6 ± 1.3

0.25

0.53

 Sex, Female (%)

40

40

1

 

 Education, years

18.0 ± 0.8

17.6 ± 0.8

0.88

0.07

 Caucasian, %

70

80

0.6

 

Clinical characteristics

 Time since diagnosis, months

91.7 ± 16.2

16.9 ± 4.8

0.007

1.37

 Time since symptom onset, months

111.3 ± 18.3

50.7 ± 7.5

< 0.001

1.98

 Cognitive function (MoCA), score

26.5 ± 0.6

23.1 ± 1.5

0.03

1.03

 MDS-UPDRS part III (video)

33.9 ± 11.7

   

 Hoehn and Yahr, score

2.4 ± 0.18

3.3 ± 0.67

0.007

1.41

 mPSPRS-21 score (video)

 

23.1 ± 5.9

  
  1. PD Parkinson’s Disease, PSP Progressive supranuclear palsy, MDS-UPDRS Movement Disorders Society Unified Parkinson’s Disease Rating Scale (without rigidity and postural stability20), mPSPRS-21 Modified virtual PSP Rating Scale; Outcomes with p values < 0.05 were considered significantly different and are shown in bold
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us